These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 30391589)

  • 1. Characterization of cryptic allosteric site at IL-4Rα: New paradigm towards IL-4/IL-4R inhibition.
    Naz S; Baig N; Khalil R; Ul-Haq Z
    Int J Biol Macromol; 2019 Feb; 123():239-245. PubMed ID: 30391589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box.
    Ul-Haq Z; Naz S; Mesaik MA
    Cytokine Growth Factor Rev; 2016 Dec; 32():3-15. PubMed ID: 27165851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure, binding, and antagonists in the IL-4/IL-13 receptor system.
    Mueller TD; Zhang JL; Sebald W; Duschl A
    Biochim Biophys Acta; 2002 Nov; 1592(3):237-50. PubMed ID: 12421669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sharing of receptor subunits and signal transduction pathway between the IL-4 and IL-13 receptor system.
    Murata T; Taguchi J; Puri RK; Mohri H
    Int J Hematol; 1999 Jan; 69(1):13-20. PubMed ID: 10641437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface.
    Hage T; Sebald W; Reinemer P
    Cell; 1999 Apr; 97(2):271-81. PubMed ID: 10219247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific antagonism of type I IL-4 receptor with a mutated form of murine IL-4.
    Schnare M; Blum H; Jüttner S; Röllinghoff M; Gessner A
    J Immunol; 1998 Oct; 161(7):3484-92. PubMed ID: 9759868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R.
    Kioi M; Kawakami K; Puri RK
    Cell Immunol; 2004 May; 229(1):41-51. PubMed ID: 15331327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor.
    Kraich M; Klein M; Patiño E; Harrer H; Nickel J; Sebald W; Mueller TD
    BMC Biol; 2006 Apr; 4():13. PubMed ID: 16640778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo design of an IL-4 antagonist and its structure at 1.9 A.
    Laporte SL; Forsyth CM; Cunningham BC; Miercke LJ; Akhavan D; Stroud RM
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):1889-94. PubMed ID: 15684085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design of a GCN4-derived mimetic of interleukin-4.
    Domingues H; Cregut D; Sebald W; Oschkinat H; Serrano L
    Nat Struct Biol; 1999 Jul; 6(7):652-6. PubMed ID: 10404222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
    Joshi BH; Leland P; Asher A; Prayson RA; Varricchio F; Puri RK
    Cancer Res; 2001 Nov; 61(22):8058-61. PubMed ID: 11719427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A synthetic peptide corresponding to a critical intracellular signaling region of the human IL-4 receptor inhibits IL-4-induced proliferation.
    Izuhara K; Sakai M; Inaba R; Imamura T; Howard M; Harada N
    Cell Immunol; 1995 Jul; 163(2):254-9. PubMed ID: 7606796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a mobile Stat6 activation motif in the human IL-4 receptor.
    Ryan JJ; McReynolds LJ; Huang H; Nelms K; Paul WE
    J Immunol; 1998 Aug; 161(4):1811-21. PubMed ID: 9712048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solution structure of human IL-13 and implication for receptor binding.
    Moy FJ; Diblasio E; Wilhelm J; Powers R
    J Mol Biol; 2001 Jun; 310(1):219-30. PubMed ID: 11419948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An antagonistic mutant of interleukin-4 fails to recruit gamma c into the receptor complex. Characterization by specific crosslinking.
    Duschl A
    Eur J Biochem; 1995 Mar; 228(2):305-10. PubMed ID: 7705343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells.
    Kawakami K; Leland P; Puri RK
    Cancer Res; 2000 Jun; 60(11):2981-7. PubMed ID: 10850446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of studies on targeting interleukin 4 receptor for central nervous system malignancy.
    Puri S; Puri S; Mahapatra AK; Hussain E; Sarkar C; Sinha S; Joshi BH
    Curr Mol Med; 2009 Aug; 9(6):732-9. PubMed ID: 19689300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond.
    Karo-Atar D; Bitton A; Benhar I; Munitz A
    BioDrugs; 2018 Jun; 32(3):201-220. PubMed ID: 29736903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-4-specific signal transduction events are driven by homotypic interactions of the interleukin-4 receptor alpha subunit.
    Lai SY; Molden J; Liu KD; Puck JM; White MD; Goldsmith MA
    EMBO J; 1996 Sep; 15(17):4506-14. PubMed ID: 8887542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic analysis of allosteric and non-allosteric effects arising from nanobody binding to two epitopes of the dihydrofolate reductase of Escherichia coli.
    Oyen D; Wechselberger R; Srinivasan V; Steyaert J; Barlow JN
    Biochim Biophys Acta; 2013 Oct; 1834(10):2147-57. PubMed ID: 23911607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.